Jingze Bio Files for Hong Kong IPO Focused on Fertility, Ophthalmology

China-based Jingze Biotech has submitted an application for a listing on the Hong Kong Stock Exchange (HKEX). Founded in 2014, the company concentrates on assisted reproduction and ophthalmology. It has completed six financing rounds since 2018, raising approximately RMB 1.04 billion (USD 153 million), with a post-money valuation of RMB 3.21 billion (USD 472 million) in its most recent round.

Jingze's pipeline includes biosimilars, modified new drugs, and innovative products. Its lead asset, JZB30 (follitropin alpha biosimilar), was approved in China in 2025 for ovulation induction and controlled ovarian stimulation in assisted reproductive technology. Exclusive commercialisation rights were licensed to King-friend Biochemical in 2025, with market launch expected in 2027. The second core asset, JZB05 (aflibercept biosimilar), is in Phase III trials, with a new drug application (NDA) filing anticipated in H2 2026.

As of April 2026, Jingze reported a net loss of approximately RMB 89 million (USD 13 million) and cash reserves of RMB 81 million.

Daily News
3SBio's Sunshine Guojian Files First Global IND for IL-23×TL1A BsAb
2026-08-10
Chinagene's Ophthalmic Gene Therapy Enters Priority Review in China
2026-08-10
BeiGene Raises Full-Year Guidance as H1 Revenue Hits RMB 22.22bn
2026-08-07
Takeda Places First OX2R Agonist for Type 1 Narcolepsy in US Market
2026-08-07
Lilly H1 2026: Tirzepatide Reaches USD 27.7bn, Revenue Up 49%
2026-08-06
Latest Report
2026 TOP-25 Drug Targets
Details